Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,
The patent application relates to Bioasis’ P97, the Company’s core polypeptide asset for transporting therapeutic agents across the BBB. These conjugates have the potential to treat central nervous system disorders and brain cancers.
“We are excited about the allowance of this patent application by the Japanese Patent Office, because this represents a significant addition to our intellectual property protection around our core assets in the major world markets including US, Europe and China,” said Company Chair and Chief Executive officer Deborah Rathjen, Ph.D. “The Bioasis business model is based on the strength of these assets, the intellectual property that is protected by our broad patent portfolio.”
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for brain cancers, including HER2+ breast cancer brain metastases, and neurodegenerative diseases. For more information about the Company, please visit www.bioasis.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006089/en/
Source: Bioasis Technologies, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190910006089/en
